Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129


Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.

Couto JI, Bear MD, Lin J, Pennel M, Kulp SK, Kisseberth WC, London CA.

BMC Vet Res. 2012 Dec 17;8:244. doi: 10.1186/1746-6148-8-244.


Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.

Onimoe GI, Liu A, Lin L, Wei CC, Schwartz EB, Bhasin D, Li C, Fuchs JR, Li PK, Houghton P, Termuhlen A, Gross T, Lin J.

Invest New Drugs. 2012 Jun;30(3):916-26. doi: 10.1007/s10637-011-9645-1. Epub 2011 Feb 22.


A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.

Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, Cen L, Li C, Lin J.

Neoplasia. 2010 Jan;12(1):39-50.


Characterization of STAT3 activation and expression in canine and human osteosarcoma.

Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA.

BMC Cancer. 2009 Mar 10;9:81. doi: 10.1186/1471-2407-9-81.


Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12.

Bid HK, Oswald D, Li C, London CA, Lin J, Houghton PJ.

PLoS One. 2012;7(4):e35513. doi: 10.1371/journal.pone.0035513. Epub 2012 Apr 17.


LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.

Zuo M, Li C, Lin J, Javle M.

Oncotarget. 2015 May 10;6(13):10940-9.


A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.

Lin L, Benson DM Jr, DeAngelis S, Bakan CE, Li PK, Li C, Lin J.

Int J Cancer. 2012 Mar 15;130(6):1459-69. doi: 10.1002/ijc.26152. Epub 2011 Aug 26.


The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells.

Ball S, Li C, Li PK, Lin J.

PLoS One. 2011 Apr 19;6(4):e18820. doi: 10.1371/journal.pone.0018820.


Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma.

Brown ME, Bear MD, Rosol TJ, Premanandan C, Kisseberth WC, London CA.

BMC Vet Res. 2015 Aug 14;11:206. doi: 10.1186/s12917-015-0505-7.


The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.

McCleese JK, Bear MD, Fossey SL, Mihalek RM, Foley KP, Ying W, Barsoum J, London CA.

Int J Cancer. 2009 Dec 15;125(12):2792-801. doi: 10.1002/ijc.24660.


Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.

Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA.

BMC Cancer. 2011 Apr 11;11:125. doi: 10.1186/1471-2407-11-125.


Impact of STAT3 inhibition on survival of osteosarcoma cell lines.

Wang X, Goldstein D, Crowe PJ, Yang JL.

Anticancer Res. 2014 Nov;34(11):6537-45.


The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines.

Fossey SL, Bear MD, Lin J, Li C, Schwartz EB, Li PK, Fuchs JR, Fenger J, Kisseberth WC, London CA.

BMC Cancer. 2011 Mar 28;11:112. doi: 10.1186/1471-2407-11-112.


Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.

Ryu K, Susa M, Choy E, Yang C, Hornicek FJ, Mankin HJ, Duan Z.

BMC Cancer. 2010 May 10;10:187. doi: 10.1186/1471-2407-10-187.


STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.

Oi T, Asanuma K, Matsumine A, Matsubara T, Nakamura T, Iino T, Asanuma Y, Goto M, Okuno K, Kakimoto T, Yada Y, Sudo A.

Int J Oncol. 2016 Dec;49(6):2275-2284. doi: 10.3892/ijo.2016.3757. Epub 2016 Nov 3.


Biological activity of dihydroartemisinin in canine osteosarcoma cell lines.

Hosoya K, Murahari S, Laio A, London CA, Couto CG, Kisseberth WC.

Am J Vet Res. 2008 Apr;69(4):519-26. doi: 10.2460/ajvr.69.4.519.


Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.

Wei CC, Ball S, Lin L, Liu A, Fuchs JR, Li PK, Li C, Lin J.

Int J Oncol. 2011 Jan;38(1):279-85.


Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA.

PLoS One. 2017 Jul 27;12(7):e0181885. doi: 10.1371/journal.pone.0181885. eCollection 2017.


Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells.

Wolfesberger B, Walter I, Hoelzl C, Thalhammer JG, Egerbacher M.

Res Vet Sci. 2006 Jun;80(3):308-16. Epub 2005 Sep 22.


Effects of lycopene on proliferation and death of canine osteosarcoma cells.

Wakshlag JJ, Balkman CE.

Am J Vet Res. 2010 Nov;71(11):1362-70. doi: 10.2460/ajvr.71.11.1362.


Supplemental Content

Support Center